Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | BMP1 | P13497 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950189 | 0.81 | ITGAV (0.40) | BCAT2HSD11B1LMNAALDH1A1KMT2A | |
| SCHEMBL1949476 | 0.79 | HSD11B1 (0.38) | BCAT2HSD11B1ALDH1A1KMT2ABMP1 | |
| SCHEMBL1925443 | 0.78 | KMT2A (0.41) | BCAT2HSD11B1ALDH1A1KMT2ABMP1 | |
| SCHEMBL1952112 | 0.75 | BMP1 (0.38) | BCAT2HSD11B1LMNABMP1 | |
| SCHEMBL1927510 | 0.75 | BMP1 (0.37) | BCAT2HSD11B1ALDH1A1BMP1 | |
| SCHEMBL1926036 | 0.75 | HSD11B1 (0.40) | BCAT2HSD11B1KMT2ABMP1MEN1 | |
| SCHEMBL1925989 | 0.73 | BMP1 (0.36) | BCAT2HSD11B1BMP1 | |
| SCHEMBL1948946 | 0.73 | BMP1 (0.38) | BCAT2ALDH1A1KMT2ABMP1MEN1 | |
| SCHEMBL1951634 | 0.72 | MMP1 (0.31) | RBP4 | |
| SCHEMBL15032878 | 0.72 | ALDH1A1 (0.41) | CA2RBP4LMNAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235636-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2011071951-A2 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-16 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235636-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, TNNC1 | BCAT2 1590/4885CA1 1354/4885CA2 425/4885 |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | TNNI3, TNNT2, TNNC1 | BCAT2 1590/4885CA1 1354/4885CA2 425/4885 |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | BCAT2 564/4885CA1 1379/4885CA2 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.